Latest News & Features
Big Pharma
The UK government has committed £160 million ($280.2 million) in funding to the life sciences after a review of the industry. 30 August 2017
Americas
Inter partes reviews filed by generic drug companies have a higher institution rate but lower invalidation rate compared to other IPRs, say Wenhua Yu, Stephen Maebius and Tianran Yan of Foley & Lardner. 30 August 2017
Asia
AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease. 29 August 2017
Americas
Gilead Sciences is to acquire Kite Pharma for $11.9 billion, after the deal was unanimously approved by both companies’ boards of directors. 29 August 2017
Big Pharma
With Brexit negotiations well under way, Nicola Dagg, global head of IP at Allen & Overy, says ensuring that all of the regulatory and compliance requirements are in place immediately after Britain leaves the EU is the most important aspect of negotiations for the life sciences. 25 August 2017
Americas
Brazil’s Ministry of Health has published the entire list of the 2017 proposals to be considered for the Partnership for Product Development. 25 August 2017
Americas
Law firm Cantor Colburn has achieved the highest rate of successful allowances for patent applications following section 101 rejections citing the Mayo and Myriad precedents, according to data compiled by research firm Juristat. 25 August 2017
Big Pharma
Pharmaceutical company AbbVie’s attempt to obtain an extension on its Humira patents has been rejected by an Australian court. 24 August 2017
Asia
The Indian Patent Office has approved pharmaceutical company Pfizer’s application to patent its Prevenar 13 (pneumococcal 7-valent conjugate) drug, despite claims by Médecins Sans Frontières that it is too obvious. 24 August 2017
Americas
The biggest challenges in the life sciences concern second medical use patents and incentives for innovation, according to Lydia McNally, vice president, head of patents, oncology at Novartis. 23 August 2017